Dermira is a biopharmaceutical company. Co. is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis. Co.'s portfolio consists of: QBREXZA, a once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis to block underarm sweat production by inhibiting sweat gland activation; Lebrikizumab, an injectable, humanized monoclonal antibody targeting interleukin 13 (IL-13) that Co. is developing for the treatment of moderate-to-severe atopic dermatitis; and other early-stage research and development programs in other areas of dermatology. The DERM stock yearly return is shown above.
The yearly return on the DERM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DERM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|